Image Source: Unsplash
 

• Bulls Ignore MACRO and Debt Ceiling Concerns for now but JUNE 1 deadline looms.
• FTC Challenges Amgen Deal and M&A models.
• Rotation Continues Out of Defensive Healthcare Stocks into InfoTech.

Investors ignored the grim pitfalls of the MACRO last week choosing to buy tech stocks in the NASDAQ-100 including new Information and Communication Sector themes such as AI and even rotating into beaten down Financials. Healthcare stocks lagged as defensive plays while small caps caught bids. Biotech stocks were rattled by an aggressive FTC posture as Lina Khan challenges the buyout of Horizon Therapeutics by Amgen (AMGN). The Company faced a double whammy also losing a bid to revive its cholesterol-lowering drug patents to French rival Sanofi SA. AMGN was down 4.09% for the week and the IBB was flat at the $130 level. The equal-weighted XBI lost about 1% for the week  but recovered on Friday to a $85.37 close. So let’s see whether the XBI can hold onto its tepid momentum as many of its component stocks would be deemed dealmaker targets.

XBI QQQ

(Click on image to enlarge)

SMID stocks would be the sector to watch as we need to get through the major MACRO test in the coming weeks. The IWM was up 1.96% for the week and the IJR was up 2.32%. Here is how some notable stocks in our Life Science Portfolio fared last week:

Acumen Therapeutics (ABOS) a new pick held close to its new trading range of about 6.

CRSPR Therapeutics (CRSP) got hit with profit taking down 2.77% for te week but is still up 16% over one month.

PACB is in a strong up-trend up 3.94% for the week and 13.94% over one month. Q1 earnings were up 17% over the same period for prior year.

Veracyte (VCYT) remains a laggard but was up 3.7% last week and is a niche play in molecular diagnostics for cancers.

No portfolio changes were made in our SMID Portfolio.

Large Cap Biopharmaceuticals came back strong on Friday and most of our top picks are near their 52-week highs: LLY MRK VRTX.  Regeneron (REGN) held up 1.97% last week despite concerns about Eylea sales longer term due to competitive pressures. ABBV remains a laggard with Humira sales weighing on the stock until we get pipeline developments.

• ASCO is coming up on June 2 so add GILD to your biopharma portfolio under $80. Gilead Sciences has beefed up its oncology pipeline with Kite Pharma.

Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.

(Click on image to enlarge)

The optimism of last week could change quickly if a bilateral debt ceiling agreement cannot be achieved. But concerns about the FED rate increases seems to have ebbed.

More By This Author:

Time To Play Small Cap Life Science Stocks
Something Happened In Biotech Last Week
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector